Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 2/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.50 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19733225 | 1.00 | NR1I3 (0.58) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL1319450 | 1.00 | NR1I3 (0.58) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL2955007 | 0.79 | CYP19A1 (0.59) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL5450814 | 0.79 | CYP19A1 (0.59) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL24451237 | 0.78 | CDK5 (0.64) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL4998832 | 0.78 | CDK5 (0.64) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL157803 | 0.78 | CDK5 (0.64) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL317924 | 0.78 | CDK5 (0.64) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL157802 | 0.78 | CDK5 (0.64) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL10343473 | 0.78 | CDK5 (0.64) | NR1I3CDK5CDK5R1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105001880-B | Aligning agent for liquid crystal and liquid crystal display element | JSR株式会社 | 2018-06-15 | — | — | CN | disclosed |
| CN-103980911-B | Aligning agent for liquid crystal, liquid crystal orientation film and liquid crystal display cells and its manufacture method | JSR株式会社 | 2017-03-01 | — | — | CN | disclosed |
| US-20160027946-A1 | OPTICAL DEVICE | JSR CORPORATION (JP) | 2016-01-28 | — | — | US | disclosed |
| CN-105001880-A | Liquid crystal aligning agent and liquid crystal display element | JSR CORP | 2015-10-28 | — | — | CN | disclosed |
| CN-103980911-A | Liquid crystal alignment agent, liquid crystal alignment film, liquid crystal display element and manufacture method thereof | JSR CORP | 2014-08-13 | — | — | CN | disclosed |
| US-8057990-B2 | Prevent, therapy for cancer; complex of tacrine compound and protein | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
| US-7927821-B2 | Methods of screening for compounds which bind G protein-coupled receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7919260-B2 | Therapy for psychological disorders; schizophrenia; cognition activators; Parkinson's disease; complex of protein and ligand | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090069228-A1 | Screening Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080305110-A1 | Novel Ligand of G Protein Coupled Receptor Protein and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080280938-A1 | Screening Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-13 | — | — | US | disclosed |
| EP-1921066-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1860185-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1857817-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1736775-A1 | NOVEL LIGAND OF G PROTEIN COUPLED RECEPTOR PROTEIN AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | NR1I3 95/4885CDK5 2008/4885CDK5R1 774/4885 |
| US-20080305110-A1 | Novel Ligand of G Protein Coupled Receptor Protein and Use Thereof | MYLK2, MUSK, GPR119 | NR1I3 648/4885CDK5 3845/4885CDK5R1 2244/4885 |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | GNRHR, PGR, MC1R | NR1I3 759/4885CDK5 449/4885CDK5R1 255/4885 |
| US-20080280938-A1 | Screening Method | STUB1, TP53, TACR2 | NR1I3 1603/4885CDK5 700/4885CDK5R1 669/4885 |
| US-20090069228-A1 | Screening Method | SAP30BP, PRLHR, UPF1 | NR1I3 3683/4885CDK5 1891/4885CDK5R1 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.